Retatrutide Shows Remarkable Weight Loss in Phase 3 TRIUMPH-1 Trial
In the phase 3 TRIUMPH-1 trial, 2339 adults with obesity or overweight and at least one weight-related comorbidity were randomized to receive retatrutide (4 mg, 9 mg, or 12 mg) or placebo over 80 weeks. Participants represented a high-severity obesity cohort, with a mean BMI of 40 kg/m² and average baseline weight of 112.7 kg.
Retatrutide produced substantial placebo-adjusted weight loss across all doses, ranging from 19.0% to 28.3%, compared with 2.2% with placebo. This translated to an average absolute weight reduction of approximately 21.4–31.9 kg versus 2.5 kg in the placebo group.
According to topline phase 3 results announced by Eli Lilly, all tested doses met the primary and key secondary endpoints for weight reduction at 80 weeks in adults with obesity or overweight.
"Obesity is a chronic disease, and people living with obesity deserve treatment options that match the complex biology of their neurometabolic disease," said Ania Jastreboff, M.D., Ph.D., Professor of Medicine & Pediatrics (Endocrinology) at the Yale School of Medicine, Director of the Yale Obesity Research Center (Y-Weight), and lead investigator. "It was impressive to see that every dose of retatrutide resulted in clinically meaningful weight reduction for nearly all participants, and people with severe obesity on the highest dose lost on average 30% of their body weight over two years. Importantly, treatment with retatrutide not only resulted in robust weight reduction, but also in clear improvements in assessed cardiometabolic health measures. For patients I see in clinic, retatrutide may potentially be a highly impactful future tool to treat their obesity and transform their health trajectory."
For the primary endpoint, participants taking retatrutide 9 mg and 12 mg lost an average of 64.4 lbs (25.9%) and 70.3 lbs (28.3%), respectively. Those taking the 4 mg dose of retatrutide, with just a single dose escalation step, lost an average of 47.2 lbs (19.0%). Notably, 65.3% of participants taking retatrutide 12 mg achieved a BMI <30, falling under the threshold for obesity at 80 weeks, including 37.5% of those who started with class 3 obesity (BMI ≥40). In a pre-specified blinded extension for those with a BMI ≥35, participants who continued on retatrutide 12 mg to 104 weeks lost an average of 85.0 lbs (30.3%).2 Additionally, retatrutide showed significant improvements from baseline across certain cardiovascular risk factors, including waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure and high-sensitivity C-reactive protein (hsCRP).
TRIUMPH-1 Efficacy Estimand Results
• Percent body weight reduction with retatrutide 4 mg was a key secondary endpoint.
• The extension period enrolled 532 participants with BMI ≥35 at baseline who had completed the main 80-week study and tolerated their assigned dose of medication.
• Participants in the trial extension received retatrutide at a maximum tolerated dose of 9 mg or 12 mg.
"TRIUMPH-1 highlights the importance of options and the potential for retatrutide to help people across various stages of their obesity journey," said
For the treatment-regimen estimand, each dose level of retatrutide led to improvements across the primary and key secondary endpoints, as well as the pre-specified extension, including:5
- Percent change in body weight at 80 weeks: -17.6% (-19.8 kg; -43.7 lbs; 4 mg); -23.7% (-26.7 kg; -58.9 lbs; 9 mg); -25.0% (-28.2 kg; -62.1 lbs; 12 mg) and -3.9% (-4.4 kg; -9.7 lbs; placebo)
- Percent change in body weight at 104 weeks: -25.7% (-30.6 kg; -67.5 lbs; 4 mg to MTD); -28.7% (-35.6 kg; -78.4 lbs; 9 mg to MTD); -29.9% (-38.1 kg; -83.9 lbs; 12 mg to MTD) and -18.9% (-22.3 kg; -49.1 lbs; placebo to MTD)
The types of adverse events seen were generally consistent with trials of other incretin-based therapies. The most common adverse events among participants treated with retatrutide (4 mg, 9 mg, 12 mg, vs. placebo, respectively) were nausea (28.6%, 38.4% and 42.4% vs. 14.8%), diarrhea (25.2%, 34.1% and 32.0% vs. 13.5%), constipation (23.8%, 25.9% and 26.1% vs. 10.9%), vomiting (10.6%, 22.8% and 25.3% vs. 4.8%), and upper respiratory tract infection (14.2%, 12.2% and 13.1% vs. 11.6%). Incidences of dysesthesia occurred in 5.1%, 12.3%, and 12.5% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 0.9% with placebo, and incidences of urinary tract infections occurred in 7.5%, 8.8%, and 8.4% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 5.3% with placebo. Events of dysesthesia and urinary tract infections were generally mild to moderate, the majority resolved during treatment, and most participants continued taking retatrutide. Discontinuation rates due to adverse events were 4.1%, 6.9%, 11.3%, with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 4.9% with placebo.
Additional TRIUMPH-1 results will be presented at the 86th annual American Diabetes Association Scientific Sessions, along with other results from Lilly's cardiometabolic pipeline. Additional detailed results will be presented at future medical meetings and published in peer-reviewed journals. More results from the TRIUMPH Phase 3 clinical trial program will be shared later this year, including data from TRIUMPH-2, which is evaluating retatrutide in adults with obesity or overweight and type 2 diabetes, and TRIUMPH-3, which is evaluating retatrutide in adults with obesity or overweight and established cardiovascular disease.
About retatrutide
Retatrutide is an investigational, once-weekly, triple hormone receptor agonist, which activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Lilly is studying retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe OSA, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Retatrutide is an investigational molecule that is legally available only to participants in Lilly's clinical trials.
